Institut Curie

Nestec S.a.

Institut National De La Sante Et De La Recherche Medicale

Olivier Jacques Lantz

Eduardo Schiffrin

Dominique Brassart

Sebastian Amigorena

Kevin Burke Miller

Emmanuel Treiner

Sebastian Diego Amigorena

The present invention relates to methods and immunonutritional compositions for preventing or mitigating paralysis of the bone marrow, caused by a tumor or neoplasm, between cycles of and after anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently preventing or moderating, bone marrow paralysis or neutropenia of a subject tumor-induced apoptosis or necrosis or other cell damage such that the innate and adaptive immune functions and normal physiology of the bone marrow are preserved, at least in part, which, in turn, lead to (i) a better tolerance and increased efficacy to treatment; (ii) transient augmentation or enhancement of immunocompetence of the immune cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened due to paralysis of the bone marrow, caused by a tumor or neoplasm.

Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor

The invention relates to methods of modulating an immune response in a mammal by modulating the activity of J&#x3b1;33 T cells or of MR1 polypeptide in vitro, ex vivo or in vivo. The invention also relates to methods of regulating the activity of immune cells, particularly of T lymphocytes and/or B lymphocytes by regulating the activity of MR1 in vitro, ex vivo or in vivo. The invention further comprises methods of screening active compounds using MR1 or fragments thereof, or nucleic acid encoding the same, or recombinant host cells expressing said polypeptide. The invention also deals with a pharmaceutical composition comprising J&#x3b1;33 T cells, MR1 polypeptide or a compound that modulates the activity of J&#x3b1;33 TCR T cells or of MR1 polypeptide and a pharmaceutically acceptable vehicle or carrier. The invention further deals with methods of diagnosis for intestinal diseases related to a defect of the activity of said J&#x3b1;33 T cells or MR1 polypeptide.

T cell subpopulation regulating gut immunity

Growing community of inventors

Paris, France

Olivier Jacques Lantz